Loading clinical trials...

Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada | Clinical Trials | Clareo Health

COMPLETED

Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada

Distribution of Risk Factors Amongst Ocular Hypertension and Open-Angle Glaucoma Patients in Canada

NCT00334750•Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

View on ClinicalTrials.gov

Summary

This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects diagnosed at study visit or within 3 months of visit with OH
•OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma)

Exclusion Criteria

•No prior treatment for OH or OAG
•No prior ocular surgery or history of ocular trauma

Locations (21)

Pfizer Investigational Site

Calgary, Alberta, Canada

Pfizer Investigational Site

Edmonton, Alberta, Canada

Pfizer Investigational Site

Edmonton, Alberta, Canada

Pfizer Investigational Site

Nanaimo, British Columbia, Canada

Pfizer Investigational Site

Vancouver, British Columbia, Canada

Pfizer Investigational Site

Williams Lake, British Columbia, Canada

Pfizer Investigational Site

Winnipeg, Manitoba, Canada

Pfizer Investigational Site

Sydney, Nova Scotia, Canada

Pfizer Investigational Site

Brampton, Ontario, Canada

Pfizer Investigational Site

Hamilton, Ontario, Canada

Key Dates

Start Date

November 1, 2007

Primary Completion Date

April 1, 2009

Completion Date

April 1, 2009

Last Updated

February 2, 2021

Enrollment

410

ACTUAL participants

Conditions

Glaucoma, Open-AngleOcular Hypertension

Interventions

There is no intervention in this study.

OTHER

DSLT for Reducing Medication in Glaucoma

NCT07390890

Primary Open Angle GlaucomaOcular Hypertension

View study

RECRUITINGNA

Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population

NCT05902871

Primary Open Angle GlaucomaOcular Hypertension+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 2, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada

Inclusion Criteria

Exclusion Criteria

DSLT for Reducing Medication in Glaucoma

Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population

Feasibility Clinical Evaluation of the Calibreye System

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

Association Between Limbal Function and Tear Proteomics in Chronic Ocular Diseases: Focusing on Glaucoma

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT